Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Colorcon
Deloitte
Merck
US Army
Federal Trade Commission
Boehringer Ingelheim
Cantor Fitzgerald
McKinsey

Generated: October 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,335,031

« Back to Dashboard

Which drugs does patent 6,335,031 protect, and when does it expire?

Patent 6,335,031 protects EXELON and is included in one NDA.

This patent has thirty-seven patent family members in twenty-seven countries.

Summary for Patent: 6,335,031
Title: TTS containing an antioxidant
Abstract:Pharmaceutical composition comprising (S)-N-ethyl-3-[1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate in free base or acid addition salt form and an anti-oxidant. Said pharmaceutical compositions may be delivered to a patient using a transdermal delivery device.
Inventor(s): Asmussen; Bodo (Bendorf-Sayn, DE), Horstmann; Michael (Neuwied, DE), Kopke; Kai (Triengen, CH), Tiemessen; Henricus L. G. M. (Weil-Haltingen, DE), Dinh; Steven Minh (Briarcliff Manor, NY), Gargiulo; Paul M. (New York, NY)
Assignee: Novartis AG (Basel, CH) LTS Lohmann Therapie-Systeme GmbH Co. KG (Neuwied, DE)
Application Number:09/291,498
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,335,031
Patent Claim Types:
see list of patent claims
Composition; Device; Use;

Drugs Protected by US Patent 6,335,031

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-001 Jul 6, 2007 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-002 Jul 6, 2007 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-005 Aug 31, 2012 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,335,031

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany9800526Jan 12, 1998

International Family Members for US Patent 6,335,031

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 223711 ➤ Try a Free Trial
Australia 2278599 ➤ Try a Free Trial
Australia 745661 ➤ Try a Free Trial
Brazil 9906920 ➤ Try a Free Trial
Canada 2315784 ➤ Try a Free Trial
China 1129427 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Federal Trade Commission
Mallinckrodt
Chinese Patent Office
Farmers Insurance
Queensland Health
Merck
Medtronic
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.